CN112342293A - 家系致病性冠心病易感基因及其体外检测的试剂和应用 - Google Patents
家系致病性冠心病易感基因及其体外检测的试剂和应用 Download PDFInfo
- Publication number
- CN112342293A CN112342293A CN202011324800.0A CN202011324800A CN112342293A CN 112342293 A CN112342293 A CN 112342293A CN 202011324800 A CN202011324800 A CN 202011324800A CN 112342293 A CN112342293 A CN 112342293A
- Authority
- CN
- China
- Prior art keywords
- heart disease
- gene
- coronary heart
- pathogenic
- sels
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 52
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 25
- 230000001717 pathogenic effect Effects 0.000 title claims abstract description 18
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 16
- 238000001514 detection method Methods 0.000 title claims abstract description 16
- 238000000338 in vitro Methods 0.000 title claims abstract description 11
- 101710095058 Selenoprotein S Proteins 0.000 claims abstract description 25
- 230000035772 mutation Effects 0.000 claims abstract description 23
- 239000002773 nucleotide Substances 0.000 claims abstract description 13
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 13
- 238000010008 shearing Methods 0.000 claims abstract description 5
- 238000012163 sequencing technique Methods 0.000 claims description 11
- 238000004458 analytical method Methods 0.000 claims description 6
- 238000011144 upstream manufacturing Methods 0.000 claims description 5
- 238000003752 polymerase chain reaction Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000012408 PCR amplification Methods 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims description 2
- 238000012216 screening Methods 0.000 abstract description 4
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 108700026220 vif Genes Proteins 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000012795 verification Methods 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 208000002251 Dissecting Aneurysm Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101000873446 Homo sapiens Selenoprotein S Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 102100034940 Selenoprotein S Human genes 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 206010002895 aortic dissection Diseases 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明涉及家系致病性冠心病检测技术领域,是一种家系致病性冠心病易感基因及其体外检测的试剂和应用,该家系致病性冠心病易感基因为发生突变的SelS基因,SelS基因的核苷酸序列如序列表SEQ ID NO:1所示,SelS基因发生突变时,其核苷酸序列表第2269位发生可剪切突变。本发明公开了基于冠心病易感基因SelS基因可剪切突变位点而开发的冠心病筛查试剂盒,检测精度和灵敏度高,利用本发明所述试剂盒可以进行冠心病的预测与辅助诊断,对于冠心病的防治具有重要的意义。
Description
技术领域
本发明涉及家系致病性冠心病检测技术领域,是一种家系致病性冠心病易感基因及其体外检测的试剂,还包括所述试剂在制备用于体外检测家系致病性冠心病易感基因的试剂盒中的应用。
背景技术
冠心病(Coronary Artery Disease,CAD)是指冠状动脉血管发生动脉粥样硬化病变,引起血管腔狭窄、阻塞或冠状动脉血管功能性改变即冠状动脉痉挛,造成心肌缺血、缺氧或坏死而导致的心脏病,又称冠状动脉粥样硬化性心脏病。CAD是一种复杂疾病,对CAD病因学、早期诊断、治疗及预防等方面的研究是目前的前沿问题。研究表明家族史是CAD的独立危险因素,遗传变异被认为是该疾病发生的直接诱因之一,因而,亟需从遗传变异角度开展CAD易感基因的研究。
SelS基因是CAD的主要易感基因已被广泛证实,但SelS基因与CAD具体作用机制尚不十分明确,在SelS基因中,任何一个碱基片段、编码蛋白的突变都会影响其在CAD疾病中的生物过程,对SelS基因致病位点或片段的精确定位有利于冠心病防治药物的筛选和研发。而新近研究表明在导致包括冠心病在内的多种人类疾病的突变中,超过90%不在蛋白质编码范围之内。作为基因调控的关键步骤之一,可变剪接广泛存在于真核生物,并参与各种生物过程,包括细胞分化凋亡和细胞程序性死亡,它也在成熟的组织和细胞压力起着重要的作用,多项研究表明,可变剪接异常可导致许多疾病。因此,研究选择性剪接事件的功能对于理解生物系统的多样性和人类疾病的分子生物学机制至关重要。
发明内容
本发明提供了一种家系致病性冠心病易感基因及其体外检测的试剂和应用,克服了上述现有技术之不足,发明人通过对一个冠心病家系进行了全外显子测序及家系连锁分析,发现了SelS基因的一个可剪切突变(IVS3+3A>T),人群中验证后,通过构建细胞模型阐明了该突变对于蛋白翻译产生的影响,为冠心病的防治研究提供了参考。鉴于此,本发明以此突变位点为检测靶点,设计引物,开发了一种SelS基因家系突变检测试剂盒,该试剂盒检测精确,灵敏度高,对冠心病的诊断与防治具有重要的指导意义。
本发明的技术方案之一是通过以下措施来实现的:一种家系致病性冠心病易感基因,该易感基因为发生突变的SelS基因,SelS基因的核苷酸序列如序列表SEQ ID NO:1所示,SelS基因发生突变时,其核苷酸序列表第2269位发生可剪切突变。
本发明的技术方案之二是通过以下措施来实现的:一种体外检测家系致病性冠心病易感基因的试剂,试剂包括引物,引物包括上游引物和下游引物,
上游引物的核苷酸序列:TATCCCAGGCTTTATGAATCGG;
下游引物的核苷酸序列:CAGAACAAACTTCACCCTCGTT。
本发明的技术方案之三是通过以下措施来实现的:一种技术方案之二所述试剂在制备用于体外检测家系致病性冠心病易感基因的试剂盒中的应用。
下面是对上述发明技术方案之三的进一步优化或/和改进:
上述试剂盒为聚合酶链式反应与限制性片段长度多态性分析相结合的试剂或聚合酶链式反应与直接测序法相结合的试剂盒。
上述试剂盒中包含PCR扩增酶及相应缓冲液。
本发明公开了基于冠心病易感基因SelS基因可剪切突变位点而开发的冠心病筛查试剂盒,检测精度和灵敏度高,利用本发明的试剂盒可以进行冠心病的预测与辅助诊断,对于冠心病的防治具有重要的意义。
附图说明
附图1为冠心病家系图谱及测序结果。
附图2为Pspl3 SELENOS WT、MUT酶切电泳图。
附图3-1为Pspl3–SELENOS-WT(野生型)的质粒测序图谱。
附图3-2为Pspl3–SELENOS-Mut(突变型)的质粒测序图谱。
附图4为Pspl3、Pspl3-mut和Pspl3-wt转染产物的质粒凝胶电泳和测序结果。
图2中,1:质粒;2:XhoI-NheI双酶切后的质粒;M:DNA Marker。
具体实施方式
本发明不受下述实施例的限制,可根据本发明的技术方案与实际情况来确定具体的实施方式。
除非特别说明,本发明中的%均为质量百分数;除非特别说明,制备过程在常温、常压状态下进行;除非特别说明,本发明中采用的试剂、方法和设备为本技术领域常规试剂、方法和设备;除非特别说明,本发明中采用的试验条件为本技术领域常规试验条件;除非特别说明,本发明中所用试剂均为市购;除非特别说明,本发明中的水为去离子水。
下面结合实施例对本发明作进一步描述:
实施例1:一种体外检测冠心病易感基因(SelS基因)突变的试剂盒,含有SelS基因的待测样品可以从来自试验者的血液获得。
实施例2:一种SelS基因家系突变检测试剂盒,所述试剂盒中包括引物、探针及扩增试剂:
所述引物序列如下:
上游引物(其核苷酸序列如序列表SEQ ID NO:2所示):TATCCCAGGCTTTATGAATCGG;
下游引物其核苷酸序列如序列表SEQ ID NO:3所示):CAGAACAAACTTCACCCTCGTT。
目前关于复杂性状疾病的研究有两种策略,连锁分析的方法和病例-对照研究。由于冠心病是一种多因素疾病,是由遗传和环境因素共同作用的结果,因而采用连锁分析较为困难。从遗传的角度分析,冠心病/心肌梗死属于复杂遗传性状疾病。对该疾病的发生起作用的因素中,除环境因素外,起作用的基因总数估计多达上百条,各个基因之间又存在着相互作用,基因又和环境之间存在相互作用。冠心病的发生具有一定的家族聚集性,但更多的是一些散发病例。所以本发明采用病例对照研究。所述病例对照研究就是在采用随机挑选的两组人群中(病例和对照)比较某等位基因的频率。
实施例3:家系致病性冠心病易感基因(SelS基因)突变位点筛查
在临床工作中,收集了一个患有遗传性冠心病的家庭(图1)。所有患病个体均存活,并接受了药物治疗。该家系为中国汉族,经一中年成年男性因不稳定型心绞痛,入院就诊询问家族史时发现。通过对家族成员进行相关检查,获得了所有亲属的详细临床资料,最终确诊6人患有冠心病,11人无冠心病。对所有血液进行了DNA提取后,通过全外显子测序及生物信息学分析后,确定了该家系的冠心病致病SelS基因一个可剪切突变(IVS3+3A>T),即核苷酸序列表(SEQ ID NO:1)第2269位发生可剪切突变。
实施例4:SelS基因可剪切突变人群验证
本研究选取2015年1月-2017年12月在新疆医科大学第一附属医院心内科住院CAD患者和无CAD的对照受试者作为验证人群进行研究。
纳入标准:CAD组:按照我院经皮冠状动脉造影证实至少有一支冠状动脉血管狭窄≥50%且无其他方面的心脏病疾患。对照组:选择2015年至2018年新疆地区人群慢性病调查中无任何心脏疾病者,两组在纳入研究前签署知情同意书。
剔除标准:CAD组:临床资料不全者及同时合并以下疾病之一者予以剔除。(如:主动脉夹层、风湿性心脏病、先天性心脏病者、多脏器功能衰竭以及具有精神障碍不能配合者)。
对照组:1、2015年至2018年新疆地区人群慢性病调查中证实患有任何心脏疾病者2、有心血管病家族史者3、吸毒者4、精神障碍者,予以剔除。
采用聚合酶链反应-直接测序的方法检测本发明位点的多态性。
方法:PCR反应体系(20μl):基因组模板DNA 50ng(来自血液标本,按照常规方法将白细胞内的DNA用苯酚-氛仿法或者用盐析法提取出来即可)
最终通过576例CAD与452例进行人群验证。我们并未在人群中发现该位点的突变,证实该位点是一个罕见突变。人群验证基线资料见表1。
反应条件如下表所示:
反应体系如下表:
ddH2O | 8.0μl |
2*Taq PCR master mix | 10.0μl |
Primer F(10nM) | 0.5μl |
Primer R(10nM) | 0.5μl |
DNA | 1.0μl |
20.0μl |
实施例5:SelS基因可剪切突变功能研究
Minigene:通指包含一个或者几个外显子以及周围调控区得序列片段。常用来研究不同的蛋白对剪切的调控功能。选择目标的外显子和内含子并进行PCR扩增,把得到的序列片段转染到多种不同的细胞中,通过杂交技术对得到的外显子移除和插入事件进行定量分析为明确该可剪切突变在细胞中的真实剪切情况。我们构建了Pspl3–SELENOS-WT(野生型)和Pspl3–SELENOS-Mut(突变型)质粒。Pspl3-SELENOS WT、Pspl3-SELENOS Mut测序结果与参比序列比对一致,质粒构建成功(见图2、3)。
实施例6SelS基因可剪切突变功能研究
将Pspl3-SELENOS野生与突变型质粒转染后Hek293T细胞后,进行采用微小基因分析技术。通过逆转录PCR扩增转录产物,并进行测序分析,确定该突变是否导致内含子剪接异常及其真正的剪接模式。从测序结果可知,c.318+3A(IVS3+3T)发生突变后,内含子剪切的位置发生了变化,向下多剪切了143个碱基,将对蛋白的翻译产生显著影响(见图4)。
以上技术特征构成了本发明的实施例,其具有较强的适应性和实施效果,可根据实际需要增减非必要的技术特征,来满足不同情况的需求。
表1病例对照组基线
Claims (5)
1.一种家系致病性冠心病易感基因,其特征在于该易感基因为发生突变的SelS基因,SelS基因的核苷酸序列如序列表SEQ ID NO:1所示,SelS基因发生突变时,其核苷酸序列表第2269位发生可剪切突变。
2.一种体外检测根据权利要求1所述的家系致病性冠心病易感基因的试剂,其特征在于试剂包括引物,引物包括上游引物和下游引物,
上游引物的核苷酸序列:TATCCCAGGCTTTATGAATCGG;
下游引物的核苷酸序列:CAGAACAAACTTCACCCTCGTT。
3.一种根据权利要求2所述的试剂在制备用于体外检测家系致病性冠心病易感基因的试剂盒中的应用。
4.根据权利要求3所述的应用,其特征在于试剂盒为聚合酶链式反应与限制性片段长度多态性分析相结合的试剂或聚合酶链式反应与直接测序法相结合的试剂盒。
5.根据权利要求3或4所述的应用,其特征在于试剂盒中包含PCR扩增酶及相应缓冲液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011324800.0A CN112342293B (zh) | 2020-11-23 | 2020-11-23 | 家系致病性冠心病易感基因及其体外检测的试剂和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011324800.0A CN112342293B (zh) | 2020-11-23 | 2020-11-23 | 家系致病性冠心病易感基因及其体外检测的试剂和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112342293A true CN112342293A (zh) | 2021-02-09 |
CN112342293B CN112342293B (zh) | 2024-02-06 |
Family
ID=74365434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011324800.0A Active CN112342293B (zh) | 2020-11-23 | 2020-11-23 | 家系致病性冠心病易感基因及其体外检测的试剂和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112342293B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103667301A (zh) * | 2013-09-06 | 2014-03-26 | 新疆医科大学第一附属医院 | 冠心病相关基因及其体外检测的试剂、制剂或试剂盒、应用 |
CN104513828A (zh) * | 2014-11-25 | 2015-04-15 | 新疆医科大学第一附属医院 | 冠心病相关基因即cyp17a1基因及其体外检测的试剂、制剂或试剂盒、应用 |
CN108004313A (zh) * | 2017-12-20 | 2018-05-08 | 新疆医科大学第附属医院 | 早发冠心病致病基因及其体外检测的试剂、制剂或试剂盒和应用 |
-
2020
- 2020-11-23 CN CN202011324800.0A patent/CN112342293B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103667301A (zh) * | 2013-09-06 | 2014-03-26 | 新疆医科大学第一附属医院 | 冠心病相关基因及其体外检测的试剂、制剂或试剂盒、应用 |
CN104513828A (zh) * | 2014-11-25 | 2015-04-15 | 新疆医科大学第一附属医院 | 冠心病相关基因即cyp17a1基因及其体外检测的试剂、制剂或试剂盒、应用 |
CN108004313A (zh) * | 2017-12-20 | 2018-05-08 | 新疆医科大学第附属医院 | 早发冠心病致病基因及其体外检测的试剂、制剂或试剂盒和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112342293B (zh) | 2024-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101679971A (zh) | 青光眼恶化风险的判定方法 | |
CN110564837B (zh) | 一种遗传代谢病基因芯片及其应用 | |
CN112538528A (zh) | 一种检测aldh2基因多态性的引物组及试剂盒 | |
EP3438283B1 (en) | Method for detecting gene mutation | |
CN108676872A (zh) | 一种与哮喘相关的生物标志物及其应用 | |
WO2022183011A9 (en) | Circular rnas for diagnosis of depression and prediction of response to antidepressant treatment | |
KR20110094041A (ko) | 정상 안압 녹내장 질환 감수성 유전자 및 그 이용 | |
KR102637032B1 (ko) | 특정 유전자의 CpG 메틸화 변화를 이용한 방광암 진단용 조성물 및 이의 용도 | |
CN112342293A (zh) | 家系致病性冠心病易感基因及其体外检测的试剂和应用 | |
EP1092782B1 (en) | Genetic screening method and genetic screening apparatus | |
JP4922778B2 (ja) | 遺伝子検査結果判定法およびプログラムおよびその装置 | |
US5882868A (en) | Method of diagnosing spinal muscular atrophy | |
TWI351436B (en) | Method for detecting a risk of the development of | |
KR102085669B1 (ko) | Cyp26c1 유전자의 메틸화 수준을 이용한 소혈관폐색증의 예측 또는 진단을 위한 정보제공방법 및 이를 위한 조성물 | |
KR102085663B1 (ko) | Wrb 유전자의 메틸화 수준을 이용한 소혈관폐색증의 예측 또는 진단을 위한 정보제공방법 및 이를 위한 조성물 | |
US20030082616A1 (en) | Apparatus and method for analyzing nucleic acids and related genetic abnormality | |
CN107385076B (zh) | 一种甲状腺功能减退致病基因突变及基于此基因突变的诊断试剂 | |
Zhong | 7 Molecular genetic testing for neuronal ceroid lipofuscinoses | |
KR101728023B1 (ko) | Pcr―ldr을 이용한 atp7b 유전자의 돌연변이 검출 | |
WO2023058522A1 (ja) | 構造多型の分析方法、プライマー対セット及びプライマー対セットの設計方法 | |
WO2018186687A1 (ko) | 생물학적 시료의 핵산 품질을 결정하는 방법 | |
KR102421788B1 (ko) | Cuedc2 유전자의 메틸화 수준을 이용한 소혈관폐색증의 예측 또는 진단을 위한 정보제공방법 및 이를 위한 조성물 | |
Nagao et al. | Improved PCR/NcoI method for the molecular diagnosis of medium chain acyl-CoA dehydrogenase deficiency using dried blood samples: two-stage amplification using two different sets of primers improves accuracy and sensitivity | |
CN116479111A (zh) | 一种先天性无瞳孔-小眼球-白内障综合征筛查方法、筛查试剂盒 | |
US20110275068A1 (en) | Method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |